Showing 301 - 310 of 454 for "" with applied filters
31 August 2018 by
The decision of the Full Federal Court in GlaxoSmithKline (GSK) Consumer Healthcare Investments (Ireland) (No 2) Limited v Generic Partners Pty Limited (2018) FCAFC 71 (May 10 2018) indicates that a mistake in a claim cannot be ignored even where the skilled person understands that a mistake has been made.
31 August 2018 by
Özge Atılgan Karakulak and Güldeniz Doğan Alkan of Gün + Partners examine the advantages and disadvantages of TÜRKSMD, a new company set up by the Turkish IP Office to value intellectual property rights
15 August 2018 by
Managing Intellectual Property will launch its research for the 2019 edition of IP STARS on September 3 2018.
08 August 2018 by
In the latest Managing IP Women in IP Interview series, Lucy Songi interviewed Astrid Gérard (Preu Bohlig & Partners), Sandra Pohlman (df-mp), Christine Kanz (Hoyng Rokh Monegier) and Cordula Schumacher (Arnold Ruess) about initiatives in Germany to address gender inequality at the workplace
02 August 2018 by
The judiciary in England and Wales has announced a pilot scheme for the new rules on disclosure that may affect intellectual property disputes
04 July 2018 by
Meet with start-up founders, entrepreneurs, investors, corporate and brand executives, and thought leaders at unbound London festival
02 July 2018 by
At the end of April 2018, Advocate General (AG) Wathelet handed down an advisory opinion regarding the first of three recent referrals to the CJEU (C-121/17). This concerns the interpretation of Article 3(a) of Regulation (EC) No 469/2009.
02 July 2018 by
Shionogi is the owner of a patent entitled Pyrimidine Derivatives (JP2648897). X filed a request for a trial for invalidation of the patent. Nippon Chemiphar intervened in the trial as a plaintiff, and AstraZeneca UK intervened in the trial in order to support the defendant.
02 July 2018 by
In a recent ruling by the Court of The Hague (ECLI:NL:RBDHA:2018:4591) a defendant/patentee has been ordered to pay the costs of nullity proceedings brought against it, despite not wishing to maintain or assert its patent.
02 July 2018 by
Following last year’s decision in Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co [2017] SGHC 322, the Intellectual Property Office of Singapore (IPOS) has recently provided clarification on the provisions of the Singapore Patents Act and the Singapore Patents Rules regarding the correction of errors in filed patent applications.